Moving from Promise to Practice in the Clinic

Trials by Therapeutic Area

Phase 2 trial for frontline treatment of advanced Hodgkin lymphoma in combination with other agents. Study #SGN35-027 is currently recruiting participants. Learn more

Phase 2 trial for frontline treatment of Hodgkin lymphoma or PTCL in patients with significant comorbidities, evaluating brentuximab vedotin as a single agent and in combination with other agents. Study #SGN35-015 is currently recruiting participants. Learn More

Phase 2 trial for treatment of Hodgkin lymphoma or PTCL in patients previously treated with brentuximab vedotin. Study #SGN35-028 is currently recruiting participants. Learn more

Phase 1/2 trial of brentuximab vedotin in combination with nivolumab. Study #SGN35-025 is ongoing, not recruiting participants. Learn More

Phase 2 CheckMate 744 trial for relapsed/refractory classical Hodgkin lymphoma in combination with nivolumab. Study #CA209-744 is currently recruiting participants. Learn more

Phase 3 EV-302 trial evaluating enfortumab vedotin for untreated metastatic urothelial cancer. Currently recruiting participants. Learn more

Phase 3 EV-301 trial evaluating enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer. Study #7465-CL0-301. Learn more

Phase 2 EV-202 trial for locally advanced or metastatic malignant solid tumors. Currently recruiting participants. Learn more

Phase 2 EV-201 trial evaluating enfortumab vedotin for locally advanced or metastatic urothelial bladder cancer. Study #SGN22E-001 is currently recruiting participants. Learn more 

Phase 1b/2 EV-103 trial evaluating enfortumab vedotin alone or with other therapies for treatment of urothelial bladder cancer. Study #SGN22E-002 is currently recruiting participants. Learn more

Phase 2 innovaTV 204 trial evaluating tisotumab vedotin for patients with previously treated, recurrent or metastatic cervical cancer. Study #GCT1015-04 is currently recruiting participants. Learn more

Phase 1b/2 innovaTV 205 trial evaluating tisotumab vedotin alone or with other therapies for patients with recurrent or stage IVB cervical cancer. Study #GCT 1015-05 is currently recruiting participants. Learn more

Phase 2 innovaTV 206 trial evaluating tisotumab vedotin in advanced solid tumors and recurrent or metastatic cervical cancer in Japanese patients. Currently recruiting participants. Learn more

Phase 2 innovaTV 207 trial evaluating tisotumab vedotin in multiple solid tumors. Study #SGNTV-001 is currently recruiting participants. Learn more

Phase 2 innovaTV 208 trial evaluating tisotumab vedotin in platinum-resistant ovarian cancer. Study #SGNTV-002 is currently recruiting participants. Learn more

Phase 2 MOUNTAINEER trial evaluating tucatinib in metastatic colorectal cancer. Study #SGNTUC-017 is currently recruiting participants. Learn more

Phase 1 trial in advanced solid tumors. Study #SGN-CD228A-001 is currently recruiting participants. Learn more

Phase 1 trial in advanced solid tumors. Study #SGN47M-001 is currently recruiting participants. Learn more

Phase 1 trial in multiple cancer types (SEA-CD40 alone or in combination with other agents). Study #SGNS40-001 is currently recruiting participants. Learn more

Phase 1 trial of SGN-TGT in advanced solid tumors and lymphomas. Study #SGNTGT-001. Learn more

HER2CLIMB-02 phase 3 trial of tucatinib vs placebo in combination with T-DM1 in patients with HER2+ breast cancer. Study #SGNTUC-016 is currently recruting participants. Learn more

Phase 2 trial in locally-advanced or metastatic triple-negative breast cancer, evaluating ladiratuzumab vedotin in combination with pembrolizumab. Study #SGNLVA-002 is currently recruiting participants. Learn more

Phase 2 I-SPY 2 trial for HER2-negative breast cancer. Study #097517 is currently recruiting participants. Learn more

Phase 1b/2 trial of multiple immunotherapy-based treatment combinations in metastatic triple-negative breast cancer. Study #CO40115 is currently recruiting participants. Learn more

Phase 1 trial evaluating ladiratuzumab vedotin as a single agent for LIV-1-positive metastatic breast cancer. Study #SGNLVA-001 is currently recruiting participants. Learn more

Phase 1 trial evaluating SEA-BCMA in relapsed/refractory multiple myeloma. Study #SGNBCMA-001 is currently recruiting patients. Learn More

 

Trials by Program

Phase 2 trial for frontline treatment of advanced Hodgkin lymphoma in combination with other agents. Study #SGN35-027 is currently recruiting participants. Learn more

Phase 2 trial for frontline treatment of Hodgkin lymphoma or PTCL in patients with significant comorbidities, evaluating brentuximab vedotin as a single agent and in combination with other agents. Study #SGN35-015 is currently recruiting participants. Learn more

Phase 2 trial for treatment of Hodgkin lymphoma or PTCL in patients previously treated with brentuximab vedotin. Study #SGN35-028 is currently recruiting participants. Learn more

Phase 2 CheckMate 744 trial for relapsed/refractory classical Hodgkin lymphoma in combination with nivolumab. Study #CA209-744 is currently recruiting participants. Learn more

Phase 1/2 trial of brentuximab vedotin in combination with nivolumab for relapsed/refractory Hodgkin lymphoma. Study #SGN35-025 is ongoing, not recruiting participants. Learn more

Phase 3 EV-302 trial evaluating enfortumab vedotin for untreated metastatic urothelial cancer. Currently recruiting participants. Learn more

Phase 3 EV-301 trial evaluating enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer. Study #7465-CL0-301. Learn more

Phase 2 EV-202 trial for locally advanced or metastatic malignant solid tumors. Currently recruiting participants. Learn more

Phase 2 EV-201 trial for locally advanced or metastatic urothelial bladder cancer. Study #SGN22E-001 is currently recruiting participants. Learn more

Phase 1b/2 EV-103 trial for urothelial bladder cancer alone or with other therapies. Enrollment in study #SGN22E-002 is currently recruiting participants. Learn more

Phase 2 innovaTV 204 trial evaluating tisotumab vedotin for patients with previously treated, recurrent or metastatic cervical cancer. Study #GCT1015-04 is currently recruiting participants. Learn more

Phase 1b/2 innovaTV 205 trial evaluating tisotumab vedotin alone and with other therapies for patients with recurrent or stage IVB cervical cancer. Study #GCT 1015-05 is currently recruiting participants. Learn more

Phase 2 innovaTV 206 trial evaluating tisotumab vedotin in advanced solid tumors and recurrent or metastatic cervical cancer in Japanese patients. Currently recruiting participants. Learn more

Phase 2 innovaTV 207 trial evaluating tisotumab vedotin in multiple solid tumors. Study #SGNTV-001 is currently recruiting participants. Learn more

Phase 2 innovaTV 208 trial evaluating tisotumab vedotin in platinum-resistant ovarian cancer. Study #SGNTV-002 is currently recruiting participants. Learn more

HER2CLIMB-02 phase 3 trial of tucatinib vs placebo in combination with T-DM1 in patients with HER2+ breast cancer. Study #SGNTUC-016 is currently recruting participants. Learn more

Phase 2 MOUNTAINEER trial evaluating tucatinib in metastatic colorectal cancer. Study #SGNTUC-017 is currently recruiting participants. Learn more

Phase 2 I-SPY 2 trial for neoadjuvant breast cancer. Study #097517 is currently recruiting participants. Learn more

Phase 2 I-SPY 2 trial for HER2-negative breast cancer. Study #097517 is currently recruiting participants. Learn more

Phase 2 trial in locally-advanced or metastatic triple-negative breast cancer, evaluating ladiratuzumab vedotin in combination with pembrolizumab. Study #SGNLVA-002 is currently recruiting participants. Learn more

Phase 1b/2 trial of multiple immunotherapy-based treatment combinations in metastatic triple-negative breast cancer. Study #CO40115 is currently recruiting participants. Learn more

Phase 1 trial evaluating ladiratuzumab vedotin as a single agent for LIV-1-positive metastatic breast cancer. Study #SGNLVA-001 is currently recruiting participants. Learn more

Phase 1 trial in advanced solid tumors. Study #SGN-CD228A-001 is currently recruiting participants. Learn more

Phase 1 trial in advanced solid tumors. Study #SGN47M-001 is currently recruiting participants. Learn more

Phase 1 trial of SEA-BCMA in relapsed/refractory multiple myeloma. Study #SGNBCMA-001 is currently recruiting participants. Learn more

Phase 1 trial in multiple cancer types (SEA-CD40 alone or in combination with other agents). Study #SGNS40-001 is currently recruiting participants. Learn more

Phase 1 trial of SGN-TGT in advanced solid tumors and lymphomas. Study #SGNTGT-001. Learn more